EP Patent

EP4116293A3 — Rho kinase inhibitors

Assigned to Kadmon Corp LLC · Expires 2023-03-29 · 3y expired

What this patent protects

The invention relates to inhibitors of ROCKI and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCKI and/or ROCK2.

USPTO Abstract

The invention relates to inhibitors of ROCKI and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCKI and/or ROCK2.

Drugs covered by this patent

belumosudil-mesylate (BELUMOSUDIL MESYLATE)

Patent Metadata

Patent number: EP4116293A3
Jurisdiction: EP
Classification: —
Expires: 2023-03-29
Drug substance claim: No
Drug product claim: No
Assignee: Kadmon Corp LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.